Form 13-F position report

BIORESTORATIVE THERAPIES IN

Reported by VANGUARD GROUP INC

Company profile Manager portfolio Source filing
BRTX CUSIP 090655606 Manager CIK 0000102909
Latest reported change

Reported 88,778 shares, up 59,048 (198.6%) from the prior quarter.

Reported value 155.7%; share count 198.6% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2025
Shares 88,778 Quarter-end amount reported
Reported value $126,952 Fair value at quarter end
Consecutive quarters held 16 Through Q3 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q4 2025 Unchanged 88,778 0 (0.0%) < 0.01% $103,870 2026-01-29
Q3 2025 Added 88,778 +59,048 (198.6%) < 0.01% $126,952 2025-11-07
Q2 2025 Unchanged 29,730 0 (0.0%) < 0.01% $49,649 2025-08-11
Q1 2025 Added 29,730 +9,258 (45.2%) < 0.01% $52,919 2025-05-09
Q4 2024 Unchanged 20,472 0 (0.0%) < 0.01% $29,275 2025-02-11
Q3 2024 Unchanged 20,472 0 (0.0%) < 0.01% $35,621 2024-11-13
Q2 2024 Unchanged 20,472 0 (0.0%) < 0.01% $41,558 2024-08-13
Q1 2024 Reduced 20,472 -100,161 (-83.0%) < 0.01% $28,251 2024-05-10
Q4 2023 Reduced 120,633 -17,185 (-12.5%) < 0.01% $209,889 2024-02-14
Q3 2023 Added 137,818 +10,862 (8.6%) < 0.01% $246,694 2023-11-14
Q2 2023 Added 126,956 +1,000 (0.8%) < 0.01% $559,876 2023-08-14
Q1 2023 Reduced 125,956 -9,090 (-6.7%) < 0.01% $428,250 2023-05-15
Q4 2022 Unchanged 135,046 0 (0.0%) < 0.01% $371,376 2023-02-10
Q3 2022 Unchanged 135,046 0 (0.0%) < 0.01% $436,000 2022-11-14
Q2 2022 Unchanged 135,046 0 (0.0%) < 0.01% $398,000 2022-08-12
Q1 2022 Reduced 135,046 -17,408 (-11.4%) < 0.01% $706,000 2022-05-13
Q4 2021 New 152,454 +152,454 (0.0%) < 0.01% $662,000 2022-02-14
Institutional context

Who else reported the position

17 managers reported BIORESTORATIVE THERAPIES IN for Q3 2025.

Manager Activity Shares Change % of reported 13F Reported value Tenure
CITADEL ADVISORS LLC New 106,210 +106,210 < 0.01% $151,880 1 qtr
VANGUARD GROUP INC This report Added 88,778 +59,048 < 0.01% $126,952 16 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 55,269 +1,007 < 0.01% $79,033 15 qtrs
Wealth Alliance Unchanged 40,000 0 < 0.01% $58,000 16 qtrs
StoneX Group Inc Reduced 37,450 -294 < 0.01% $54,303 16 qtrs
Virtu Financial LLC Added 24,351 +12,319 < 0.01% $35,000 2 qtrs
STATE STREET CORPORATION Unchanged 20,459 0 < 0.01% $29,256 11 qtrs
Tower Research Capital LLC TRC Added 3,619 +2,341 < 0.01% $5,248 15 qtrs
ADVISOR GROUP HOLDINGS INC Unchanged 2,193 0 < 0.01% $3,959 14 qtrs
WELLS FARGO & COMPANY MN New 1,000 +1,000 < 0.01% $1,450 1 qtr
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2025
Filed
November 07, 2025
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
0
Shared
39,452
None
49,326

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.